Johnson & Johnson : JNJ

All Johnson & Johnson Articles

1240 Articles

Jon C. Ogg | Dec 13, 2019 at 12:25 PM EST

Meet the Preliminary 2020 Dogs of the Dow

One theme that investors love in good times and in bad is dividend investing. One strategy that has been around…

Chris Lange | Dec 9, 2019 at 10:40 AM EST

Why These 3 Biotechs More Than Doubled on Monday

Monday was a breakout day for a few biotech companies. Some made absolutely massive runs, practically doubling and then some.…

Jon C. Ogg | Nov 20, 2019 at 8:55 AM EST

Top Analyst Upgrades and Downgrades: Amarin, Baker Hughes, Canopy Growth, Home Depot, Intelsat, J&J, Replimune, Schlumberger, Transocean and More

Wednesday's top analyst upgrades, downgrades and initiations include Amarin, Baker Hughes, Canopy Growth, Home Depot, Intelsat, Johnson & Johnson, Replimune,…

Jon C. Ogg | Nov 18, 2019 at 10:50 AM EST

How Dow 28,000 Can Rapidly Become Dow 30,000 and Even Higher in 2020

Despite the never-ending election cycle, there actually is a clear path for the Dow to hit 30,000 as soon as…

Jon C. Ogg | Nov 4, 2019 at 11:20 AM EST

As the Dow Hits All-Time High, Over Half of Dow Stocks Keep Disappointing Investors

With markets at all-time highs, it's important to consider the winners and losers. In this case, many stocks in the…

Lee Jackson | Nov 4, 2019 at 6:50 AM EST

Why Goldman Sachs Enhanced Income Strategy May Be Perfect for 2020

Goldman Sachs may have the best strategy for investors for 2020. Here are five stocks that look like great ideas…

Jon C. Ogg | Oct 29, 2019 at 5:12 PM EDT

J&J Gets $10 Billion Gift as Lab Results Show No Asbestos in Baby Powder

Johnson & Johnson has found itself involved in more controversy than the company would prefer to see. But it seems…

Jon C. Ogg | Oct 19, 2019 at 6:45 AM EDT

How Biotech and Big Pharma Have Upside Heading Into Earnings

Credit Suisse and Merrill Lynch made calls in the biotech and pharmaceutical space last week, ahead of coming earnings reports.

Jon C. Ogg | Oct 16, 2019 at 8:45 AM EDT

Top Analyst Upgrades and Downgrades: Adobe, Alibaba, Amazon, AT&T, Comcast, Delphi, DocuSign, J&J, JPMorgan, T-Mobile, Verizon, Wells Fargo and More

Wednesday's top analyst upgrades, downgrades and initiations included Adobe, Alibaba, Amazon.com, AT&T, Comcast, Delphi Technologies, DocuSign, Johnson & Johnson, JPMorgan,…

Chris Lange | Oct 15, 2019 at 10:29 AM EDT

Johnson & Johnson Offers a Strong Start to Earnings Season

Johnson & Johnson reported better than expected quarterly results before the markets opened on Tuesday.

Chris Lange | Oct 14, 2019 at 12:10 PM EDT

What to Expect When Johnson & Johnson Reports Tuesday

Johnson & Johnson is scheduled to report its most recent quarterly results before the markets open on Tuesday, and analysts'…

Chris Lange | Oct 13, 2019 at 6:50 AM EDT

Coca-Cola, Goldman Sachs, IBM, Johnson & Johnson and More Dow Stocks Reporting This Week

Seven of the 30 Dow Jones industrial average components are scheduled to report their latest quarterly reports this week.

Jon C. Ogg | Oct 11, 2019 at 8:50 AM EDT

Top Analyst Upgrades and Downgrades: Apple, Canopy Growth, CrowdStrike, Delta, J&J, Rio Tinto, Roku, Square, Tilray, Twilio and More

Friday's top analyst upgrades, downgrades and initiations included Apple, Canopy Growth, CrowdStrike, Delta Air Lines, Johnson & Johnson, Rio Tinto,…

Chris Lange | Oct 9, 2019 at 12:25 PM EDT

Johnson & Johnson Has a Lot on Its Hands After $8 Billion Court Ruling

Johnson & Johnson shares dropped on Wednesday following the announcement that a jury has awarded $8 billion in damages to…

Chris Lange | Oct 2, 2019 at 10:50 AM EDT

Johnson & Johnson May Have Just Dodged a Big Opioid Bullet

One analyst issued a fairly bullish report in response to Johnson & Johnson's announcement of a $10 million settlement with…

1 … 29 30 31 32 33 … 83

Johnson & Johnson : JNJ

All Johnson & Johnson Articles

Meet the Preliminary 2020 Dogs of the Dow

Why These 3 Biotechs More Than Doubled on Monday

Top Analyst Upgrades and Downgrades: Amarin, Baker Hughes, Canopy Growth, Home Depot, Intelsat, J&J, Replimune, Schlumberger, Transocean and More

How Dow 28,000 Can Rapidly Become Dow 30,000 and Even Higher in 2020

As the Dow Hits All-Time High, Over Half of Dow Stocks Keep Disappointing Investors

Why Goldman Sachs Enhanced Income Strategy May Be Perfect for 2020

J&J Gets $10 Billion Gift as Lab Results Show No Asbestos in Baby Powder

How Biotech and Big Pharma Have Upside Heading Into Earnings

Top Analyst Upgrades and Downgrades: Adobe, Alibaba, Amazon, AT&T, Comcast, Delphi, DocuSign, J&J, JPMorgan, T-Mobile, Verizon, Wells Fargo and More

Johnson & Johnson Offers a Strong Start to Earnings Season

What to Expect When Johnson & Johnson Reports Tuesday

Coca-Cola, Goldman Sachs, IBM, Johnson & Johnson and More Dow Stocks Reporting This Week

Top Analyst Upgrades and Downgrades: Apple, Canopy Growth, CrowdStrike, Delta, J&J, Rio Tinto, Roku, Square, Tilray, Twilio and More

Johnson & Johnson Has a Lot on Its Hands After $8 Billion Court Ruling

Johnson & Johnson May Have Just Dodged a Big Opioid Bullet

Here’s What It Costs to Buy Back Your Fridays

5 Underperforming Dividend Kings Offer Big Passive Income and Huge Total Return Potential

Here Are Thursday’s Best Wall Street Analyst Research Calls: Adobe, Chevron, Dana, Honeywell Aerospace, Mobility Global, Ni Source, Palantir, SpaceX, and More

Here's What It Costs to Buy Back Your Fridays

Retiring to Costa Rican Beaches with $950,000 Is Within Reach

Despite Franchisees Struggling, McDonald’s Dividend Keeps Rising

Here’s What It Costs to Buy Back Your Fridays

Johnson & Johnson : JNJ

All Johnson & Johnson Articles

Meet the Preliminary 2020 Dogs of the Dow

Why These 3 Biotechs More Than Doubled on Monday

Top Analyst Upgrades and Downgrades: Amarin, Baker Hughes, Canopy Growth, Home Depot, Intelsat, J&J, Replimune, Schlumberger, Transocean and More

How Dow 28,000 Can Rapidly Become Dow 30,000 and Even Higher in 2020

As the Dow Hits All-Time High, Over Half of Dow Stocks Keep Disappointing Investors

Why Goldman Sachs Enhanced Income Strategy May Be Perfect for 2020

J&J Gets $10 Billion Gift as Lab Results Show No Asbestos in Baby Powder

How Biotech and Big Pharma Have Upside Heading Into Earnings

Top Analyst Upgrades and Downgrades: Adobe, Alibaba, Amazon, AT&T, Comcast, Delphi, DocuSign, J&J, JPMorgan, T-Mobile, Verizon, Wells Fargo and More

Johnson & Johnson Offers a Strong Start to Earnings Season

What to Expect When Johnson & Johnson Reports Tuesday

Coca-Cola, Goldman Sachs, IBM, Johnson & Johnson and More Dow Stocks Reporting This Week

Top Analyst Upgrades and Downgrades: Apple, Canopy Growth, CrowdStrike, Delta, J&J, Rio Tinto, Roku, Square, Tilray, Twilio and More

Johnson & Johnson Has a Lot on Its Hands After $8 Billion Court Ruling

Johnson & Johnson May Have Just Dodged a Big Opioid Bullet

Here’s What It Costs to Buy Back Your Fridays

5 Underperforming Dividend Kings Offer Big Passive Income and Huge Total Return Potential

Here Are Thursday’s Best Wall Street Analyst Research Calls: Adobe, Chevron, Dana, Honeywell Aerospace, Mobility Global, Ni Source, Palantir, SpaceX, and More

Featured Reads

Here's What It Costs to Buy Back Your Fridays

Retiring to Costa Rican Beaches with $950,000 Is Within Reach